Purpose:To investigate the effect of p53 gene transfection and 1,2∶5,6-dianhydro-3,4-diacetylgalactitol (DADAG) on the growth of hepatocellular carcinoma(HCC). Methods:The HCC line HLE that were transfected with plasmid pUHD10-3 recombined with wt-p53 gene by lipofectamine-mediated were cultured in medium containing DADAG. 3-(4,5-Dimethy-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium-bromid(MTT) technique was used to analyse the growth of HCC cells. Results:The growth of HCC cell line HLE were inhibited after being transfected with wt-p53 gene,and 67.68% of the cells were inhibited on the fourth day. 53.09% of HCC cell line HLE were inhibited when they were exposed to DADAG. When the HCC cell line HLE transfected with wt-p53 gene were exposed to DADAG,85.37% of the cells were inhibited. Conclusions:The inhibition efficiency of HCC was enhanced by the combination of DADAG and wt-p53 gene transfection.

Objective To compare the safety and efficacy of insulin degludec (IDeg) with those of insulin glargine (IGlar) in insulin-naive subjects with type 2 diabetes (T2DM).Methods This was a 26-week,randomized,open-label,parallel-group,treat-to-target trial in 560 Chinese subjects with T2DM (men/women:274/263,mean age 56 years,mean diabetes duration 7 years) inadequately controlled on oral antidiabetic drugs (OADs).Subjects were randomized 2:1 to once-daily IDeg (373 subjects) or IGlar(187 subjects),both in combination with metformin.The primary endpoint was changes from baseline in glycosylated hemoglobin(HbA1c) after 26 weeks.Results Mean HbA1c decreased from 8.2％ in both groups to 6.9％ in IDeg and 7.0％ in IGlar,respectively.Estimated treatment difference (ETD) of IDegIGlar in change from baseline was-0.10％ points (95％ CI-0.25-0.05).The proportion of subjects achieving HbA1c ＜ 7.0％ was 56.3％ and 49.7％ with IDeg and IGlar,respectively [estimated odds ratio of IDeg/IGlar:1.26 (95 ％ CI 0.88-1.82)].Numerically lower rateof overall confirmed hypoglycaemia and statistically significantly lower nocturnal confirmed hypoglycemia were associated with IDeg compared with IGlar,respectively [estimated rateratio of IDeg/IGlar 0.69 (95％ CI 0.46-1.03),and 0.43 (95％ CI 0.19-0.97)].No differences in other safety parameters were found between the two groups.Conclusions IDeg was non-inferior to IGlar in terms of glycaemic control,and was associated with a statistically significantly lower rate of nocturnal confirmed hypoglycaemia.IDeg is considered to be suitable for initiating insulin therapy in Chinese T2DM patients on OADs requiring intensified treatment.Clinical trail registration Clinicaltrials.gov,NCT01849289.